Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone

Basit Öğe Kaydı
dc.contributor.authorBolaman, Zahit
dc.contributor.authorKöseoǧlu, Mehmet Hicri
dc.contributor.authorAyyıldız, Orhan
dc.contributor.authorKadıköylü, Gürhan
dc.contributor.authorSönmez, Hulki Meltem
dc.contributor.authorDemir, Süleyman
dc.contributor.authorMüftüoğlu, Ekrem
dc.date.accessioned2024-04-24T17:56:31Z
dc.date.available2024-04-24T17:56:31Z
dc.date.issued2002
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractFourteen patients with blastic phase chronic myelogenous leukemia received combination chemotherapy with mitoxantrone 5 mg/m2 intravenously daily for 3 days, cytosine arabinoside 100 mg/m2 intravenously over 2 hours bid for 7 days and high dose methylprednisolone 1000 mg/day intravenously for 5 days. The patients' mean age was 52 ± 10 (range 34-64) and Philadelphia chromosome was positive in all. Five patients (35%) achieved complete remission and four patients (28%) had a partial remission. Overall remission rate was 64%. The mean survival was 11.1 ± 8.6 months (median 13) for all patients, 19.4 ± 4.0 months (median 19) for those achieving a complete remission, 12.50 ± 5.7 months (median 14) for patients with partial remission and 1.8 ± 1.8 months (median 2) for the unresponsive patients. Two of 5 unresponsive patients died early after the second course of remission induction. The treatment regimen was generally well tolerated. Marrow hypoplasia was observed in 9 (64%) patients and 7 (50%) had febrile episodes. Non-myelosupressive toxicity of the regimen was acceptable. Nausea and vomiting were observed in 8 (57%) patients and 3 (21%) patients developed flushing due to cytosine arabinoside. These results suggest that the regimen with mitoxantrone, cytosine arabinoside and high dose methylprednisolone in remission-induction of blastic phase chronic myelogenous leukemia may be a valid option that may also improve overall prognosis.en_US
dc.identifier.citationBolaman, Z., Köseoǧlu, M. H., Ayyıldız, O., Kadıköylü, G., Sönmez, H. M., Demir, S. ve diğerleri. (2002). Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone. Haematologia, 32(1), 49-57.
dc.identifier.doi10.1163/156855902760262763
dc.identifier.endpage57en_US
dc.identifier.issn0017-6559
dc.identifier.issue1en_US
dc.identifier.pmid12243555
dc.identifier.scopus2-s2.0-0036901814
dc.identifier.scopusqualityN/A
dc.identifier.startpage49en_US
dc.identifier.urihttps://doi.org/10.1163/156855902760262763
dc.identifier.urihttps://hdl.handle.net/11468/23556
dc.identifier.volume32en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.relation.ispartofHaematologia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBlastic phaseen_US
dc.subjectChronic myelogenous leukemiaen_US
dc.subjectHigh dose methylprednisoloneen_US
dc.titleTreatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisoloneen_US
dc.titleTreatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu